About Azurity Pharmaceuticals
Azurity Pharmaceuticals is a Healthcare company based in Woburn (United States) founded in 1999. Generic drugs are manufactured by Azurity Pharmaceuticals in the US. Azurity Pharmaceuticals has raised $20 million across 1 funding round from investors including Ampersand Capital Partners. Azurity Pharmaceuticals has completed 4 acquisitions, including Arbor pharma, Covis Pharma and Silvergate Pharma. Its website azurity.com draws about 21 thousand monthly visits. Azurity Pharmaceuticals offers products and services including XIFYRM and FIRVANQ. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified. Its legal entity is Azurity Pharmaceuticals, Inc.
Company details
Azurity Pharmaceuticals was founded in 1999 and is headquartered in Woburn, United States. Operations are conducted in the pharmaceutical sector, with a focus on the production of generic drugs. Manufacturing processes are centered on developing and supplying affordable medications to meet market needs. The companys domain, azurity.com, supports its digital operations and information dissemination. Geographic activities remain primarily within the United States.
- Headquarters Woburn, United States
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website azurity.com
- Social LinkedIn X
- Legal Name Azurity Pharmaceuticals, Inc
- Annual Revenue$64.85 K (USD)-33as on Jul 26, 2023
- Net Profit$40.74 K (USD)-41as on Jul 26, 2023
- Total Equity Funding$20M (USD)
in 1 rounds
- Latest Funding Round$20M (USD), Series A
Dec 2014
- Investors
- Investments & AcquisitionsArbor pharma
& 3 more
Products & Services of Azurity Pharmaceuticals
Azurity Pharmaceuticals offers a comprehensive portfolio of products and services, including XIFYRM and FIRVANQ.
An IV non-steroidal anti-inflammatory drug is offered for the management of moderate-to-severe pain in adults
A product is provided for treating bacterial infections, forming part of the company's diversified pharmaceutical offerings
Funding Insights of Azurity Pharmaceuticals
Azurity Pharmaceuticals has successfully raised a total of $20M through 1 strategic funding round. The most recent funding activity was a Series A round of $20 million completed in December 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $20M
- Total Rounds 1
- Last Round Series A — $20M
- First Round $20M
(Dec 2014)
- Investors Count 1
All 1 funding rounds of Azurity Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2014 | $20M | Series A | – | – |
1 investors in total: 1 institutional.
Investors in Azurity Pharmaceuticals
Azurity Pharmaceuticals has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Ampersand Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Ampersand Capital Partners is focused on investments in healthcare and life sciences. | ampersandcapital.com | Boston, United States |
Investor details for Azurity Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Azurity Pharmaceuticals
Azurity Pharmaceuticals has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Arbor pharma, Covis Pharma and Silvergate Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses | covispharma.com | Zug, Switzerland | 2011 | Mar 2025 | •••• | |
Specialty generic drugs are manufactured with focus on complex injectables. | slayback-pharma.com | West Windsor Township, United States | 2011 | Sep 2023 | •••• | |
Dose-form innovations for established medicines are developed. | arborpharma.com | Atlanta, United States | 2006 | Aug 2021 | •••• | |
Pharmaceutical products for pediatric patients are manufactured by the company. | silvergatepharma.com | Greenwood Village, United States | 2010 | Jun 2019 | •••• |
Complete acquisition details for Azurity Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Azurity Pharmaceuticals
6 dated milestones of Azurity Pharmaceuticals across 26 years, from founding to its latest funding, stage changes and deals.
- Founded Azurity Pharmaceuticals is founded.
- Funding First funding round of $20.0M.
- Acquisition Acquires Silvergate Pharma.
- Acquisition Acquires Arbor pharma.
- Acquisition Acquires Slayback Pharmaceuticals.
- Acquisition Acquires Covis Pharma.
Web traffic of Azurity Pharmaceuticals
The website of Azurity Pharmaceuticals (azurity.com) receives about 20.6K visits a month and ranks #1,531,516 among all websites worldwide, #2,028 in Biotechnology and Pharmaceuticals.
- Monthly visits20.6K
▲ 16.3% vs previous month
- Unique visitors8.4K
per month
- Global rank#1,531,516
among all websites
- Category rank#2,028
Health · Biotechnology and Pharmaceuticals
- Bounce rate58%
- Pages per visit1.6
- Average visit39 sec
- DevicesDesktop 40% · Mobile 60%
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as Azurity Pharmaceuticals (Traditional Health & Nutrition) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Manufacturer of generics formulations | 2002 | Bridgewater, New Jersey, United States | USD 3.02 B | 8,300 | ||
Biosimilar therapeutics are developed for oncology and autoimmune diseases. | 2010 | Redwood City, California, United States | USD 143.62 M | USD 42.17 M | 228 | |
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | Bridgewater, New Jersey, United States | USD 5.1 B | 13,500 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Azurity Pharmaceuticals
Azurity Pharmaceuticals was founded in 1999 and raised its 1st funding round 15 years after it was founded.
Azurity Pharmaceuticals is headquartered in Woburn, United States. It is registered at Woburn, Massachusetts, United States.
Azurity Pharmaceuticals is a funded company, having raised a total of $20M across 1 funding round to date. The company's 1st funding round was a Series A of $20M, raised on Dec 2014.
Annual revenue of Azurity Pharmaceuticals is $64.85K as on Jul 26, 2023.
Azurity Pharmaceuticals was founded in 1999 and is headquartered in Woburn, United States. Operations are conducted in the pharmaceutical sector, with a focus on the production of generic drugs. Manufacturing processes are centered on developing and supplying affordable medications to meet market needs. The companys domain, azurity.com, supports its digital operations and information dissemination. Geographic activities remain primarily within the United States.
Azurity Pharmaceuticals offers XIFYRM and FIRVANQ.
Azurity Pharmaceuticals has made 4 acquisitions, including Arbor pharma, Covis Pharma, and Silvergate Pharma.
Azurity Pharmaceuticals has 1 investor. Key investors include Ampersand Capital Partners.
Azurity Pharmaceuticals operates through Azurity Pharmaceuticals, Inc.